The NHS Commissioning Board (operating under the name of NHS England)
NHS National Generic Pharmaceuticals Wave 13
This is a contract result notice, not an open opportunity. Details from the official award data.
The procurement contact named on the official notice.
Potential periods of call-offs under the framework agreement:<br/><br/>Transition (Everolimus)<br/>CESW: 1 March 2022 – 30 September 2023 (19 months)<br/>LSNE: 1 March 2022 – 31 January 2023 (11 months)<br/>NWLN: 1 March 2022 – 31 January 2023 (11 months)<br/><br/>Oral Products plus non-parenterals<br/>All Regions: 1 March 2022 - 31 May 2024 (27 months)<br/><br/>Hospital Only Products<br/>CESW: 1 February 2022 – 30 September 2023 (20 months)<br/>LSNE: 1 February 2022 – 31 May 2024 (28 months)<br/>NWLN: 1 February 2022 – 31 January 2023 (12 months)
Make the case to bid
Reveal who to approach at The NHS Commissioning Board (operating under the name of NHS England), and generate a go-to-market strategy from their news, accounts and people.
Ask me about this tender, the buyer, who wins their work, or whether you should bid.
- OCID
- ocds-h6vhtk-02be28
- Stage
- award · Awarded
- Source
- Find a Tender
- Buyer ref
- 001128-2022
Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.
Who wins this kind of work
The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.
Top suppliers & buyers in Medical Equipment & Pharmaceuticals
The NHS Commissioning Board (operating under the name of NHS England)’s tender network
Assembling the network…